A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart

Phase 1 Completed 24 enrolled AstraZeneca Parexel · collab

RandomizedCrossoverTriple-blindTreatment

Summary

This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval

Timeline

Start: 2020-03-03
Primary completion: 2020-08-21
Completion: 2020-08-21

Publications

Parkinson J, Dota C, Kallgren C, Gottfridsson C, Bjursell M, Perl S, Kӧrnicke T, Rekic D, Johansson S. Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling. Br J Clin Pharmacol. 2023 Jun;89(6):1747-1755. doi: 10.1111/bcp.15637. Epub 2023 Jan 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Verinurad	Small molecule	24 mg	Oral
Subject	Verinurad	Small molecule	40 mg	Oral
Background	Allopurinol	Small molecule	300 mg	Oral

Indications

No indication recorded.